The Quickvue At-Home OTC COVID-19 test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-COV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests. This test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (ns) swab specimens from individuals aged 14 years and older or with adult-collected anterior ns samples from individuals aged 2 years or older. Positive results indicate the presence of virus-specific proteins, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses and the agent detected may not be the definite cause of disease. Individuals who test positive should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary. Negative results should be treated as presumptive, do not rule out SARS-COV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of an individuals recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. Individuals should provide all results obtained with this product to their healthcare provider for public health reporting. This product has been authorized only for the detection of proteins from SARS-COV-2, not for any other viruses or pathogens. This product has not been FD cleared or approved, but it has been authorized by FDA for use under an Emergency Use Authorization (EUA). This product is also only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of covid-19 under section 564(b)(1) of the federal food, drug and cosmetic act, 21 u.s.c. 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. Test type: Lateral Flow Immunoassay Specimen type: Nasal (NS) swab specimen Turnaround time: The test is intended to be read at 10 minutes. If the test is read before this or is read more than 5 minutes after the indicated read time, results may be inaccurate (false negative, false positive, or invalid) and the test should be repeated.